此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the Treatment of Community-Acquired Pneumonia in Elderly Patients

2026年11月15日 更新者:Wei Zhao、Shandong University

A Randomized Superiority Study Comparing Model-Guided Optimized Dosing With Empirical Dosing of Piperacillin/Tazobactam in Elderly Patients With Community-Acquired Pneumonia

This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection.

Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours.

But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better.

The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule.

Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug.

Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.

研究概览

研究类型

介入性

注册 (估计的)

118

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Shandong
      • Jinan、Shandong、中国、250000
        • 招聘中
        • Shandong Provincial Public Health Clinical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 至 110年 (年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age ≥ 65 years;
  • Clinically diagnosed or highly suspected community-acquired pneumonia (CAP). CAP clinical diagnostic criteria: All three of the following must be met:

Onset in the community setting;

At least one of the following clinical manifestations:

New-onset cough, sputum production, or worsening of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, or hemoptysis; Fever; Signs of pulmonary consolidation and/or moist rales; Peripheral white blood cell count > 10×10⁹/L or < 4×10⁹/L, with or without left shift; Chest imaging showing new patchy infiltrates, lobar/segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion.

For patients aged ≥ 65 years with a body temperature < 38°C, the presence of clear clinical signs of pneumonia and abnormal chest X-ray findings will also be considered meeting the inclusion criteria.

  • At least one of the following risk factors for drug-resistant pathogens:

Comorbidities such as chronic cardiopulmonary disease, diabetes mellitus, renal failure, etc.; Use of broad-spectrum antibiotics within the past 3 months; History of repeated hospitalizations or residence in a long-term care facility;

  • Patients are required to initiate intravenous empiric antimicrobial therapy, and piperacillin-tazobactam is considered appropriate empiric treatment.
  • Expected length of hospital stay ≥ 72 hours;
  • Signed informed consent form.

Exclusion Criteria:

  • Highly suspected or confirmed fungal pneumonia or viral pneumonia;
  • Concurrent use of broad-spectrum antibiotics with similar antibacterial spectra, including cefoperazone-sulbactam, imipenem-cilastatin, meropenem, biapenem and others;
  • Patients with severe allergy to β-lactams and history of severe adverse reactions;
  • End-stage diseases with expected survival time shorter than the treatment course, such as advanced malignant tumors and end-stage organ failure;
  • Severe renal insufficiency with creatinine clearance <40 mL/min, or patients receiving continuous renal replacement therapy (CRRT);
  • Any other conditions deemed ineligible for enrollment by investigators.

Post-randomization exclusion criteria:

  • Isolated fungal infection;
  • Isolated viral infection;
  • Patients with confirmed pathogenic bacteria resistant to piperacillin-tazobactam (PIP/TAZO) during the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:guideline-based conventional dosing

Control arm (guideline-based conventional dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 3-hour intravenous infusion every 8 hours (q8h), for a total treatment course of 5-14 days.

实验性的:Model-guided optimized dosing

Intervention arm (model-guided optimized dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 4-hour intravenous infusion every 6 hours (q6h), for a total treatment course of 5-14 days. This arm adopts increased dosing frequency and prolonged infusion duration compared with the control arm.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
The proportion of patients achieving the predefined pharmacodynamic (PD) target.
大体时间:up to 1 month
up to 1 month

次要结果测量

结果测量
大体时间
Clinical improvement rate after 3 days of empiric therapy
大体时间:Day 3
Day 3
Length of hospital stay
大体时间:through hospital discharge, an average of 2 weeks
through hospital discharge, an average of 2 weeks
Treatment success rate
大体时间:through hospital discharge, an average of 4 weeks
through hospital discharge, an average of 4 weeks
Adverse event (AE) incidence rate
大体时间:through end of study-drug treatment, an average of 7 days
through end of study-drug treatment, an average of 7 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月17日

初级完成 (估计的)

2027年5月31日

研究完成 (估计的)

2027年5月31日

研究注册日期

首次提交

2026年5月20日

首先提交符合 QC 标准的

2026年11月15日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月15日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data (IPD) will not be shared due to patient privacy and confidentiality regulations, and the lack of specific informed consent for public data sharing.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅